TCM
IMPL

Towercrest Capital Management’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Towercrest Capital Management’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,500
Closed -$615K – 98
2021
Q3 		$615K Buy
+50,500
New +$733K 0.12% 56

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $375M AUM 72.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Towercrest Capital Management's IMPL Position: Q4 2021 in Review

Towercrest Capital Management sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2021, closing a stake of 50,500 shares — an estimated $615K sold.

Towercrest Capital Management first reported a position in IMPL in Q3 2021 and held it in 1 quarter. The position peaked at $615K in Q3 2021. 45 funds tracked by Wall St. Rank hold IMPL as of Q4 2021.

  • Towercrest Capital Management reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Towercrest Capital Management sold 50,500 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2021, an estimated $615K.
  • Towercrest Capital Management first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Towercrest Capital Management's Impel Pharmaceuticals Inc. Common Stock position peaked at $615K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2021.

Based on Towercrest Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.